review of alternative access for transcatheter aortic ...review of alternative access for...
TRANSCRIPT
![Page 1: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/1.jpg)
Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR)
Aamir Shah, MD, FACS
Associate Director, Aortic Program
Cardiothoracic and Vascular Surgery Cedars-Sinai Medical Center Los Angeles, CA
![Page 2: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/2.jpg)
Background
• Transcatheter Aortic Valve Replacement (TAVR) has become accepted clinical therapy for patients with severe aortic stenosis who are inoperable, high or intermediate surgical risk based on randomized PARTNER A/B/2 trials
• Trans-femoral TAVR is precluded in up to 10-15% of patients with significant aorto-iliac disease
• Alternative approaches have included trans-apical and trans-aortic with increased morbidity
• Current alternative access approaches include subclavian arteries, carotid arteries, and IVC
![Page 3: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/3.jpg)
Multiple Access Sites for TAVR
Carotid
Aortic (TAo)
Trans-septal
IVC to Ao Entry Femoral (TF)
Apical (TA)
Subclavian
![Page 4: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/4.jpg)
Multi-Slice CT
Iliofemoral assessment
TF
Non-calcified Cross-sectional
Diameter > 5.5 mm
No high arch angulation
No significant aortic disease
Alternative access assessment
<inclusion criteria>
CSMC Protocol for Access Planning
![Page 5: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/5.jpg)
CSMC Protocol for Access Planning
Cross sectional Diameter > 5 mm
Diameter > 7 mm if functioning LITA bypass graft
Aortoventricular angle < 70 degrees
No excessive calcification or tortuosity
Left Subclavian assessment
Trans-Subclavian
Trans-aortic assessment Trans-apical assessment
Annulus to access > 70 mm
Calcium free spot in “ TAo zone”
Annulus to apex > 45 mm
No significant LV dysfunction
LV cavity > 40 mm in diastole
TAo TA
Trans-caval assessment
![Page 6: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/6.jpg)
Subclavian with patent LIMA Recommended
Minimum Luminal Diameter
Personal Communication Medtronic CoreValve System
![Page 7: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/7.jpg)
Transapical and Transaortic TAVR TVT Registry 2011-2014
• 4953 pts undergoing TA or TAo TAVR from 2011-2014 in STS ACC TVT Registry
• Mean age 82.8 +/- 6.8 yrs
• STS median predicted mortality Tao 8.8%, TA 7.4%
• TAo increased risk unadjusted 30 day mortality 10.3 vs 8.8%; 1 yr mortality 30.3% vs 25.6%
• No risk adjusted difference in mortality, stroke, or readmission
• Stroke 2.2%, major vascular complications 0.3%
![Page 8: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/8.jpg)
Trans-carotid TAVR
• French TC TAVR Registry, n=93 pts from 2009-2013
• Mean age 79
• STS predicted mortality 7.1%
• Procedural mortality 3.1%
• 30 day mortality 6.3%
• No major vascular complications
• 30 day CVA/TIA rate 6.3%
Mylotte et al, JACC Cardiovasc Interventions 2016;9(5); 472-80
![Page 9: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/9.jpg)
TAVR CSMC
TAVR TF n= 1541 (95.1%)
TAVR Subclav n= 49 (3.0%) TAVR TAo
n= 22 (1.36%)
TAVR TA n= 8 (0.05%)
TAVR 6/14- 7/17; n=1620
![Page 10: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/10.jpg)
CSMC Subclavian Access TAVR
Characteristic Total n=49 (%)
Age 81.3 +/- 8.1
Female 61%
STS Predicted Mortality 10.2 +/- 5.8
BMI (kg/m2) 25.9 +/- 6.0
DM 30.6%
HTN 95.5%
CAD 55.1%
Prior CABG 24.5%
CRI (HD) 34.7% (6.1%)
Cerebrovascular Dx 36.7%
![Page 11: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/11.jpg)
Baseline Characteristics
Characteristic Total n=49, (%)
TTE
EF (%) 56.5 +/- 12.6
Peak gradient (mm Hg) 78.3 +/- 25.7
Mean Gradient (mm Hg) 43.9 +/- 16.8
AVA (cm2) 0.70 +/- 0.25
CT access artery diam (mm)
R Iliofemoral MLD (mm) 4.0 +/- 1.2
L Iliofemoral MLD (mm) 4.1 +/- 1.2
L/R Subclavian artery MLD (mm) 5.8 +/- 1.0
![Page 12: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/12.jpg)
Iliofemoral Access
![Page 13: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/13.jpg)
Left Subclavian Artery Assessment
![Page 14: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/14.jpg)
Procedure Example
① ②
③ ④ Sutured graft Graft puncture
![Page 15: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/15.jpg)
Cerebral Embolic Protection
![Page 16: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/16.jpg)
![Page 17: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/17.jpg)
Results Outcome Total n = 49 (%)
Opeerative Mortality 0 (0%)
Hospital Mortality 2 (4.0%)
TAVR procedural success 100%
Aborted subclavian access 1 (2.0%)
Right subclavian access 6 (12.2%)
Post TAVR mean gradient (mmHg)
5.0 +/- 4.1
LOS post TAVR (days) 4.4 +/- 2.9
Paravalvular Leak (PVL)
None-trace 81.6%
Mild 12.2 %
Mild-moderate 6.1 %
Moderate or greater 0 %
![Page 18: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/18.jpg)
TAVR Valve Type
Outcome Total n= 49 (%)
Valve type
Balloon expandable 34 (69.4%)
Sapien XT 18 (36.7%)
Sapien 3 16 (32.7%)
Self expandable 15 (30.6%)
CoreValve 13 (26.5%)
Portico 2 (4.1%)
![Page 19: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/19.jpg)
Complications
Complication Total n= 49 (%)
Stroke Disabling 1 (2.0%)
Stroke Non-disabling 1 (2.0%)
Myocardial infarction 0 (0%)
Major bleeding complication 0 (0%)
Vascular complication (LSA dissection) 2 (4.1%)
Acute Kidney Injury – stage 3 2 (4.1%)
New PPM 4 (8.2%)
Brachial plexus neuropathy 1 (2.0%)
![Page 20: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/20.jpg)
Transcaval Access for TAVR
![Page 21: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/21.jpg)
Transcaval TAVR
• 100 patients, 2014-2016
• Female 58%
• Ineligible TF access, high risk transthoracic access
• CAD 89%, Prior cardiac surgery 44%
• STS predicted mortality 9.6%
Greenbaum et al, JACC 2017;69(5):511-21
![Page 22: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/22.jpg)
Outcomes at 30 days
• Transcaval access success 99%
• Device success 98/99 pts
• 8 pt required covered stents
• Hospital mortality 4%, Stroke 5%
• 30 day mortality 8%
• Life threatening bleeding 7%, Major vascular complication 13%
• Median LOS 4 days Greenbaum et al, JACC 2017;69(5):511-21
![Page 23: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/23.jpg)
Transcaval case CSMC
![Page 24: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/24.jpg)
Transcaval TAVR
![Page 25: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/25.jpg)
![Page 26: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/26.jpg)
![Page 27: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/27.jpg)
Conclusions
• This series demonstrates feasibility and of safety utilizing subclavian artery for TAVR access
• Facility with all alternative access options allows appropriate treatment of high risk patients who are ineligible for transfemoral TAVR with acceptable operative risk
![Page 28: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/28.jpg)
Thank you
![Page 29: Review of Alternative Access for Transcatheter Aortic ...Review of Alternative Access for Transcatheter Aortic Valve Replacement (TAVR) Aamir Shah, MD, FACS Associate Director, Aortic](https://reader033.vdocuments.site/reader033/viewer/2022041720/5e4e08fc56e0b11f0b3c3429/html5/thumbnails/29.jpg)
Conclusion